In fact, in 2003, anti-CD19 2nd generation CAR-T cells provided the first preclinical evidence for antitumor activity against chronic lymphocytic leukemia (CLL) cells, co-stimulated by CD80 and IL-15 [18,19]. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.